注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
北海康成制药有限公司是一家主要从事罕见病疗法的研发和商业化的中国公司。该公司的主营业务是医疗产品的开发、生产、推广及销售。该公司的主要产品是用于治疗胶质母细胞瘤(GBM)的糖基化融合蛋白CAN008。该公司的产品主要用于亨特氏综合症(MPS II)等罕见病、罕见肿瘤等领域。该公司还从事基因疗法的开发。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Peng Kuan Chan | 59 | 2021 | Independent Non-Executive Director |
Richard James Gregory | 65 | 2020 | Independent Non-Executive Director |
James Qun Xue | 53 | 2018 | Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board |
James Arthur Geraghty | 68 | 2018 | Independent Non-Executive Director |
Kan Chen | 40 | 2021 | Non-Executive Director |
Edward Hu | 60 | 2022 | Non-Executive Director |
Mark A. Goldberg | 69 | - | Member of Strategic Advisory Board |
Anthony Amato | - | 2022 | Member of Scientific Advisory Board |
Sushrut Waikar | - | 2022 | Member of Scientific Advisory Board |
Lan Hu | 54 | 2022 | Independent Non-Executive Director |
Guangping Gao | - | 2020 | Member of Strategic Advisory Board |
Robert Colvin | - | 2022 | Member of Scientific Advisory Board |
Richard Polisson | - | 2022 | Member of Scientific Advisory Board |
Jean Francis | - | 2022 | Member of Scientific Advisory Board |
Brian Weinshenker | - | 2022 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核